
    
      This is a multicenter, retrospective chart review study of de-identified drug response marker
      results and a limited data set of clinical outcome data. Data from approximately 512 cases
      will be collected from approximately 30 sites and correlated to the secondary endpoints
      identified in order to produce a training set that will incorporate additional improvements
      to the existing ChemoFx scoring system. The outcome of progression free survival will be
      defined as the period of time between the first dose of chemotherapy following the report of
      the marker result until clinical progression or death. Objective response will be measured
      from the first dose of chemotherapy following the report of the marker result until
      progression or change in therapy.
    
  